Replimune Group (NASDAQ:REPL) Shares Down 2.9% - Here's Why

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s stock price fell 2.9% during trading on Tuesday . The stock traded as low as $8.43 and last traded at $8.51. 418,476 shares were traded during mid-day trading, a decline of 52% from the average session volume of 866,690 shares. The stock had previously closed at $8.77.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Replimune Group currently has an average rating of "Buy" and a consensus target price of $19.43.

Replimune Group Stock Down 0.1 %

The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a market cap of $696.99 million, a P/E ratio of -2.95 and a beta of 1.26. The stock has a 50 day moving average price of $10.24 and a 200 day moving average price of $11.66.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its stake in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its position in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares during the period. GAMMA Investing LLC increased its stake in Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Replimune Group during the 4th quarter worth about $117,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.